Nervous tissues from both humans with neurodegenerative diseases (NDD) and animals with genetic models of human NDD, such as rare monogenic causes of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD), show activated microglia, suggesting a potential causal role for inflammation in pathogenesis of NDD. We performed paired-end (PE) RNA sequencing (RNA seq) of total RNA's extracted from frozen sections of cervical spinal cords from ALS and CTL subjects, frontal cortical gray matter ribbons of AD and CTL subjects, and ventral midbrains of PD and CTL subjects. Trimmed PE reads were aligned against the hg38 human transcriptome using Tophat2/Bowtie2 (ALS) or HISAT2 (AD and PD) and quantitated with Cufflinks. PE reads were also aligned using Bowtie2 against genomes from representative species of Toxoplasma gondii and Trichinella sp. T6 (parasitic infectious agents), Babesia microti and Borrelia burgdorferi (tick-vector borne agents), and Treponema denticola and Porphyromonas gingivalis, agents causing chronic gingivitis. Primary aligned reads of each agent in each tissue sample were quantitated with SAMtools. We found small percentages (<0.1%) of transcriptomes aligned with B. microti, B. burgdorferi, T. denticola, and P. gingivalis genomes and larger percentages aligned with T. gondii (0.1-0.2%) and Trichinella sp. T6 (1.0-1.1%) genomes. In AD specimens, but in no others, primary aligned transcriptome percentages, although small, approached significance for being greater in AD compared to CTL samples for B. burgdorferi (p = 0.067) and P. gingivalis (p = 0.068). Genes' expressions in 
INTRODUCTION
Microglia are CNS-resident immune cells that can serve both beneficial (reduction of immune responses) and detrimental (activation of neurotoxic immune responses) functions (all references cited are restricted to those of last 3 years, 2016-2018) (Asiimwe et al., 2016; Beamer et al., 2016; Calsolaro and Edison, 2016; Casas et al., 2016; Chen S.H. et al., 2016; Chen W.W et al., 2016; Puentes et al., 2016; Ransohoff, 2016; Rothaug et al., 2016; Su et al., 2016; Toledano et al., 2016; Trias et al., 2016; Ulrich and Holtzman, 2016; Wes et al., 2016; Au and Ma, 2017; Bagyinszky et al., 2017; Bickford et al., 2017; Blank and Prinz, 2017; Blaylock, 2017; Bolos et al., 2017; Cerami et al., 2017; Clayton et al., 2017; Collier et al., 2017; Colonna and Butovsky, 2017; Du et al., 2017; Guerriero et al., 2017; Han et al., 2017; Herz et al., 2017; Jay et al., 2017; Joers et al., 2017; Keren-Shaul et al., 2017; Kober and Brett, 2017; Koellhoffer et al., 2017; Labandeira-Garcia et al., 2017; Lall and Baloh, 2017; Lannes et al., 2017; Nissen, 2017; Plaza-Zabala et al., 2017; Roser et al., 2017; Sochocka et al., 2017; Sorce et al., 2017; Spittau, 2017; Thompson and Tsirka, 2017; Tse, 2017; van Horssen et al., 2017; Wolf et al., 2017; Yan et al., 2017; Yang et al., 2017; Aguilera et al., 2018; Baufeld et al., 2018; Bisht et al., 2018; Crisafulli et al., 2018; Deczkowska et al., 2018; Edison and Brooks, 2018; Labzin et al., 2018; Maccioni et al., 2018; Niranjan, 2018; Selles et al., 2018; Solleiro-Villavicencio and Rivas-Arancibia, 2018; Spagnuolo et al., 2018; Taylor et al., 2018) .
Because activated microglia can produce known neurotoxic substances, such as tumor necrosis factor alpha (TNF-α) (Asiimwe et al., 2016; Islam, 2017; Tse, 2017) , microglial presence has suggested that immune-mediated neurodegeneration may contribute to disease origin and/or progression in human neurodegenerative diseases (NDD) (op cit above).
By sorting brain immune cells and carrying out massively parallel RNA sequencing (RNA seq) on these cells over the course of disease progression in the 5X FAD mouse model of human AD Keren-Shaul et al. (2017) , demonstrated the TREM2-independent ("Stage 1") and subsequent TREM2-dependent ("Stage 2") emergence of "disease-associated microglia, " or DAM, during clinical and pathological progression (TREM = "triggering receptor expressed on myeloid cells").
Such DAM appeared to originate from "homeostatic" microglia (see Figure 6 in Keren-Shaul et al., 2017) , then due to unknown causes, progressed to Stage 1 DAM by TREM2-independent mechanisms, followed by TREM2-mediated progression into Stage 2 DAM. At Stages 1 and 2, DAM exhibited unique genotypes, consisting mainly of upregulated genes. Deczkowska et al. (2018) subsequently reviewed the field of DAM.
We acquired postmortem samples of CNS tissues from sporadic NDD cases and carried out moderate-high density PE RNA sequencing on total RNA to seek systems biology understandings of disease pathogenesis in ALS, AD, and PD Brohawn et al., 2016; Bennett and Keeney, 2017; Ladd et al., 2017 ) (see also 1 ). We now sought to query these data to test the hypothesis that subclinical CNS infections with common agents could be associated with microglial activation and presence of DAM. To do so, we sought (using the Bowtie2 aligner) to determine if any of the PE RNA seq reads aligned with bacteria or parasite genomes downloaded from the NIH genome site. We then assayed the expression in each NDD tissue sample (of CTL) of genes associated with homeostatic microglia, Stage 1 or Stage 2 DAM as defined by Keren-Shaul et al. (2017) .
RESULTS
In our RNA seq studies we obtained between ∼56 and ∼172 million PE reads (based on Bowtie2 alignments). From these PE reads, we found wide variation in the number of reads primarily aligned with infectious agents' genomes. When expressed as % of total PE reads, we observed between ∼3.2 × 10 −6 (B. microti) and ∼1.1 (Trichinella sp. T6). These results are summarized in Figures 1, 2 , which show mean % aligned reads in each of the three NDD tissue specimens, expressed as mean ±SEM. In the case of AD frontal cortex samples, but in no others, we observed a difference between AD and CTL cases for Borrelia burgdorferi and Porphyromonas gingivalis that approached significance (p = 0.067 for B. burgdorferi and p = 0.068 for P. gingivalis, both by unpaired t-test). In no other pair did we observe a situation where NDD >CTL for transcript abundance of infectious disease agents. Because all of our total RNA extracts were treated with DNAase and used cDNA's generated for multiplex RNA seq reads, we are confident that alignments represent NDD tissue transcripts (i.e., RNA) aligned to infectious agent genomes (i.e., DNA). We did note a substantial difference in abundance of transcripts aligned to the genome of Trichinella sp. T6 compared to all others examined.
In the second part of our study, we examined expressions of genes associated with homeostatic microglia and Stage 1 and Stage 2 disease-associated microglia (DAM), as defined by Keren-Shaul et al. (2017) ; see their Figure 6 ) and discussed by Deczkowska et al. (2018) . Figure) ; and (c) expression of Stage 2 DAM genes (lower graph of each Figure) . Each gene's expression is shown as % of mean CTL tissue samples expression (±SEM) for each postmortem tissue. ALS gene expressions were derived from a Tophat2/Bowtie2/Cufflinks pipeline and the AD and PD expressions were derived from a HISAT2/Cufflinks pipeline. In all cases the genes were aligned against the most current available (hg38) version of the human genome.
Two-way ANOVA tests showed significant variation by gene for the ALS (homeostatic microglial, Stages 1 and 2 DAM) and AD (homeostatic microglial and Stage 1 DAM) samples but not for the PD samples. Individual unpaired t-tests revealed significant changes for all gene groups in the ALS and two gene groups in the AD, but none for the PD samples. We note that for the Stage 1 DAM analysis in the AD samples, we found a significant decrease in expression of P2RY12 (purinergic receptor P2Y12), also observed by Keren-Shaul et al. (2017) .
DISCUSSION
By querying ∼52 to ∼172 million RNA seq paired-end (PE) reads in tissues from the three major adult NDD's, we found that highly variable numbers of primary alignments could be found for several infectious agents known to affect humans. This is a limited list of infectious agents, and we appreciate that others could have been selected. These agents were selected based on documented infections in humans and availability of genomes. CNS involvement with parasitic infections, in particular, is known for Toxoplasma and Trichinella (Dzikowiec et al., 2017) .
Our initial study of this approach yielded both very low frequencies of alignments (for B. burgdorferi, P. gingivalis, and Treponema denticola) and much higher alignment frequencies (for Trichinella sp. T6). With one exception (AD), we found no evidence that alignment frequencies in a NDD tissue set was greater than in CTL tissues from the same brain region. These findings suggest it is unlikely that sub-clinical infections could account for inflammation associated with NDD tissues we examined with RNA-seq. This assessment is tempered by the possibility that RNA species from the infectious agents could have been produced earlier in the NDD illnesses we studied, since we were restricted to CNS tissues from end-stage diseases.
By comparing expression of genes reported by KerenShaul et al. (2017) to be associated with homeostatic microglia, or Stage 1 or Stage 2 DAM, we observed significant changes in our AD and ALS but not PD populations. These findings suggest but do not prove that homeostatic microglia and DAM are present in our postmortem tissue samples. More stringent proof of homeostatic microglia or DAM existence would require RNA seq of individually identified microglia in each tissue sample. This approach is not feasible with our current logistical and economic constraints.
There are multiple limitations to our study. These include:
1. Use of postmortem materials. RNA seq is always problematic in these tissues, likely due to variable post-mortem intervals, inevitable RNA decay during frozen sectioning, and other unknown variations. We did attempt to use comparable RNA quality specimens, but in our hands these are always less than optimal (compared, for instance, to freshly isolated cells in culture In addition, if our results can be extrapolated to multiple NDD's, they suggest a common qualitative mechanism that could be therapeutically approached.
MATERIALS AND METHODS
Our methods for tissue acquisition, RNA seq analyses and bioinformatics have been described in multiple publications Brohawn et al., 2016 Brohawn et al., , 2018 Bennett and Keeney, 2017; Ladd et al., 2017) . The particular tissue sets for ALS Brohawn et al., 2016; Ladd et al., 2017) , AD (Bennett and Keeney, 2017) 2 and PD (see text footnote 1) have been previously described. Briefly, tissues from persons with sporadic NDD's were stored at −80 degrees and blocks dissected from these unfixed, frozen specimens. Frozen 20-micron tissue sections from these unfixed tissue blocks were placed into Qiazol buffer and stored at −80 degrees until RNA isolation was carried out (miRNeasy, Qiagen). An on-column DNAase step was included for each sample. RNA quality was analyzed by gel electrophoresis. Illumina sequencing libraries were constructed according to manufacturer instructions and quantitated by qPCR, either by us (ALS/CTL cervical spinal cord) or by Cofactor Genomics (AD/CTL frontal cortex, PD/CTL ventral midbrain) and paired-end (PE) Illumina sequencing was carried out by Cofactor Genomics, Inc. 3 Compressed (gz) PE reads in fastq format were trimmed of Illumina sequence adapters (Trimmomatic R ) and analyzed for expression based on the hg38 human genome by Tophat2/Bowtie2 (ALS) or HISAT2 (Kim et al., 2015) and quantitated with Cufflinks. In other experiments, trimmed PE reads were aligned using Bowtie2 against genomes of infectious agents, downloaded in FASTA format from the NIH website 4 "genome." Bowtie2-build was used to construct Bowtie2 index files for each genome, samtools was used to convert the SAM files to BAM files, and the samtools command samtools view -c -F 260 x.bam was used to quantitate the number of primary aligned reads in each sample for each NDD. All bioinformatics assays were performed "blind" and were based solely on sample number ID (not disease state). All graph constructions, correlations and statistical assays were performed in Prism 7 5 .
DATA AVAILABILITY
All tissues were acquired commercially from National Disease Resource Interchange (http://ndriresource.org; NDRI) (ALS/CTL cervical spinal cords); under the auspices of an IRBapproved collection protocol (most AD/CTL and some PD/CTL), or were declared exempt from IRB oversight (some AD/CTL and some PD/CTL). All sequencing data discussed are the property of Neurodegeneration Therapeutics, Inc., and were acquired with private funds. Untrimmed, compressed (gz) FASTQ sequencing files are available to all legitimate investigators, following request to the corresponding author (JB), completion of a Material Transfer Agreement and provision of either a FTP URL or a memory storage device capable of storing 2 TB of data. Trimmed, processed BAM files following Trimmomatic and Tophat2/Bowtie2 analyses are also available upon reasonable request.
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